NCNA VS AIM Stock Comparison

Performance

NCNA
10/100

NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.

AIM
10/100

AIM returned -5.30% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

NCNA
94/100

4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.

AIM

"Analyst Price Targets" not found for AIM

Sentiment

NCNA
65/100

NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.

AIM

"Sentiment" not found for AIM

Technicals

NCNA
11/100

NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

AIM
50/100

AIM receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

NCNA
10/100

NCNA has missed earnings 7 times in the last 20 quarters.

AIM
10/100

AIM has missed earnings 15 times in the last 20 quarters.

Profit

NCNA
10/100

Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AIM
10/100

Out of the last 20 quarters, AIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NCNA
54/100

NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

AIM
47/100

AIM has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NuCana plc American Depositary Share Summary

Nasdaq / NCNA

Healthcare

Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

AIM ImmunoTech Inc. Summary

Healthcare

Biotechnology

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Power up your portfolio